|
|
Article: Diagnocure announces fiscal 2007 second quarter results - Quarterly net loss down 29%.
- Article from:
- PR Newswire
- Article date:
- June 6, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Ticker Symbol: CUR
QUEBEC CITY, June 6 /PRNewswire-FirstCall/ -- DiagnoCure Inc. (TSX: CUR), a leading developer and provider of innovative high-value molecular diagnostic assays for the detection and management of cancer, today announced its financial results for the second quarter ended April 30, 2007.
Highlights of the Quarter
Gen-Probe, DiagnoCure's exclusive sub-licensee for diagnostic applications of the PCA3 genetic marker, is now distributing analyte specific reagents (ASR) for PCA3 in the U.S., and is selling its fully CE-marked PROGENSA(TM) PCA3 in Europe. Major U.S. laboratories now selling PCA3-based tests include; the Dianon unit ...